SEC filings and other documents

Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership.

Net loss narrowed to $3.5M as R&D and G&A expenses fell sharply; cash reserves at $65M.

Reproxalap nears FDA decision, targeting rapid relief in dry eye and allergy with AbbVie partnership.

Net loss decreased to $33.8M in 2025; FDA decision on reproxalap and AbbVie option remain key catalysts.

Lead immune-modulating therapies advance toward key regulatory and clinical milestones.

FDA extends reproxalap PDUFA date for additional trial data; review and partnership terms unchanged.

PDUFA decision for Reproxalap could trigger a $194M AbbVie deal and market expansion.

FDA decision on dry eye therapy nears, with robust pipeline and AbbVie partnership advancing.

Reproxalap NDA review and AbbVie partnership drive a robust immunology pipeline forward.

RASP-targeted therapies advance in clinical trials, with reproxalap nearing FDA review and AbbVie partnership.

Reproxalap nears approval with rapid efficacy, while pivotal pipeline trials drive future catalysts.

RASP modulation pipeline advances with reproxalap poised for FDA decision and rapid market impact.

Lead assets reproxalap and ADX-2191 advance toward commercialization and rare disease markets.

Q2 2025 net loss narrowed, cash runway extends into 2027, FDA decision on reproxalap pending.

Lead RASP modulator reproxalap achieved Phase 3 success and is positioned for regulatory review.

NDA resubmission for reproxalap in dry eye disease is planned after strong new trial results.

Q1 2025 net loss widened to $9.9M as Aldeyra advances reproxalap and awaits FDA and AbbVie decisions.

Reproxalap met its phase III endpoint, rapidly reducing ocular discomfort in dry eye disease.

FDA requests more efficacy data for reproxalap; NDA resubmission targeted for mid-year.

Reproxalap approaches FDA approval with a robust pipeline advancing in immunology and retina.

Dry eye milestone and AbbVie deal near, with broad immunology pipeline advancing.

Aldeyra's 2024 net loss rose to $55.9M as it advances reproxalap toward FDA approval and a key AbbVie deal.

Late-stage eye drug developers outlined novel therapies and 2024 launch milestones.